biomedicina slovenica

re="ANN ONCOL" : 48

  1. Šeruga Boštjan; Pond Gregory Russell; Hertz Paul C; Amir Eitan; Ocaña Alberto; Tannock Ian
    Comparison of absolute benefits of anticancer therapies determined by snapshot and area methods
    2012 ►
  2. Smith IE; Borštnar Simona
    First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2251 patients
    2011 ►
  3. Erčulj N; Kovač V; Hmeljak J; Dolžan V
    The influence of platinum pathway polymorphisms on the outcome in patients with malignant mesothelioma
    2012 ►
  4. Šeruga Boštjan; Hertz PC; Wang L; Booth CM; Cescon David W; Krzyzanowska M; Tannock Ian
    Absolute benefits of medical therapies in phase III clinical trials for breast and colorectal cancer
    2010 ►
  5. Šeruga Boštjan; Hertz PC; Le LW; Tannock Ian
    Global drug development in cancer: a cross-sectional study of clinical trial registries
    2010 ►
  6. Rabaglio M; Sun Z; Price KN; Čufer T
    Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial
    2009 ►
  7. Gondos Adam; Primic-Žakelj Maja
    Trends in cancer survival in 11 European populations from 1990 to 2009: #a #model-based analysis
    2009 ►
  8. Gruber G; Cole BF; Castiglione-Gertsch M; Holmberg SB; Lindtner J; Golouh R; Collins J; Crivellari D; Thurlimann B; Simoncini E; Fey MF; Gelber RD; Coates AS; Price KN; Goldhirsch A; Viale G; Gusterson BA; Eržen D; Čufer T; Majdič E; Štabuc B; Lamovec J; Jančar J; Vrhovec I; Kramberger M; Novak J; Naglas M; Senčar M; Červek J; Šebek S; Cerar O; Plesničar A; Zakotnik B
    Extracapsular tumor spread and the risk of local, axillary and supraclavicular recurrence in node-positive, premenopausal patients with breast cancer
    2008 ►
  9. Colleoni M; Li SZ; Gelber Richard D; Coates Alan S; Castiglione-Gertsch M; Price Karen; Lindtner Jurij; Rudenstam Carl-Magnus; Crivellari Diana; Collins Joseph; Pagani Olivia; Simoncini E.; Thürlimann Beat; Murray Elizabeth; Forbes John Alexander; Eržen Darja; Holmberg Stig B.; Veronesi A.; Goldhirsch Aron; Plesničar Andrej; Majdič Elga; Štabuc Borut; Golouh Rastko; Lamovec Janez; Jančar Janez; Vrhovec Ivan; Kramberger Marta; Novak Janez; Naglas M; Senčar Mojca; Červek Jožica; Šebek Slava; Cerar Olga; Čufer Tanja
    Timing of CMF chemotherapy in combination with tamoxifen in postmenopausal women with breast cancer
    2005 ►
  10. Čufer Tanja
    Reducing the risk of late recurrence in hormone-responsive breast cancer
    2007 ►
  11. Arko Darja; Čas-Sikošek Nina; Bali Robert; Gorišek Borut; Takač Iztok
    An open-label study to investigate the efficacy and safety of epoetin beta 30,000 IU once weekly in anaemic patients with metastatic breast cancer
    2006 ►
  12. Keshaviah A.; Lindtner Jurij
    CA 15-3 and alkaline phosphatase as predictors for breast cancer recurrence: a combined analysis of seven International Breast cancer study group trials
    2007 ►
  13. Snoj Nataša; Drev Primož; Golouh Rastko; Čufer Tanja
    The response to treatment with anastrozole and tamoxifen in HER2 positive breast cancer patients
    2005 ►
  14. Ebert Maja; Borštnar Simona; Červek Jožica; Čufer Tanja; Pajk Bojana
    Feasibility and toxicity of adjuvant chemotherapy in breast cancer patients over 70 years old
    2005 ►
  15. Globokar Tina; Borštnar Simona; Čufer Tanja; Pajk Bojana; Červek Jožica
    CNS metastases in breast cancer patients treated with trastuzumab
    2005 ►
  16. Primic-Žakelj M; Zadnik V; Žagar T
    Is cancer epidemiology different in western Europe to that in eastern Europe?
    2005 ►
  17. Atalay G; Dirix L; Biganzoli L; Beex L; Nooij M; Cameron D; Lohrisch C; Čufer T; Lobelle JP; Mattiaci MR
    The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC trial 10951, 'Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients'
    2004 ►
  18. Scheithauer W; McKendrick J; Begbie S; Borner M; Burns WI; Burris HA; Cassidy J; Jodrell D; Koralewski P; Štabuc B
    Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial
    2003 ►
  19. Micheli A; Coebergh JW; Mugno E; Massimiliani E; Sant M; Oberaigner W; Holub J; Storm HH; Pleško I; Pompe-Kirn V
    Eurpean health systems and cancer care
    2003 ►
  20. Škof Erik; Grašič-Kuhar Cvetka
    Ovarian germ cell tumours: survival and fertility
    2003 ►
  21. Paridaens R; Dirix L; Lohrisch C; Beex L; Nooij M; Cameron D; Biganzoli L; Čufer T; Duchateau L; Hamilton A; Lobelle JP; Piccart M
    Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer
    2003 ►
  22. Lutz JM; Francisci S; Mugno E; Usel M; Pompe-Kirn V; Coebergh JW; Bieslka-Lasota M
    Cancer prevalence in Central Europe: the EUROPREVAL study
    2003 ►
  23. Capocaccia R; Colonna M; Corazziari I; de Angelis R; Francisci S; Micheli A; Mugno E; Pompe-Kirn V
    Measuring cancer prevalence in Europe: the EUROPREVAL project
    2002 ►
  24. Micheli A; Mugno E; Krogh V; Quinn MJ; Coleman M; Hakulinen T; Gatta G; Berrino F; Capocaccia R; Pompe-Kirn V
    Cancer prevalence in European registry areas
    2002 ►
  25. Colleoni Marco; Smith Heather; Castiglione-Gertsch Monica; Gelber Richard D; Sauerbrei Willi; Coates Alan S; Schumacher Martin; Bonetti Marco; Bastert Gunter; Lindtner Jurij
    Duration of adjuvant chemotherapy: a joint analysis of two randomized trails investigating 3 versus 6 courses of cyclophosphamide methotrexate and 5-fluorouracil (CMF) without endocrine treatment
    2000 ►
  26. Žgajnar J; Gatzemeier W; Costa A
    Will the sentinel lymph node (SLN) stand a second time - SLN biopsy in breast cancer patients with isolated local recurrence following breast conserving therapy and previous SLN procedure
    2001 ►
  27. Čufer T; Bračko M
    Myeloid metaplasia of the breast
    2001 ►
  28. Čufer T
    Adjuvant therapy of breast cancer: update
    1999 ►
  29. Primic-Žakelj M
    Screening mammography for early detection of breast cancer
    1999 ►
  30. Tomšič Radka
    Prognostic factors in patients with non-Hodgkin's lymphoma of the head and neck in stage I and II
    1999 ►
  31. Čufer T; Lazarev A; El-Ghamrawy K; Doval D; Vrba Z; Shah P; Kurtova A; Ghilezan N; Chalofti I; Blanc C
    Preliminary data of a phase II trial of taxotere (TXT) 100 or 75 mg/m2 as 2nd line chemotherapy (CT) in patients (pts) with metastatic breast cancer (MBC) with stratification according to prognosis factors
    1998 ►
  32. Goldhirsch A; Eržen D; Cerar O; Štabuc B; Golouh R; Lamovec J; Šebek S; Kramberger M; Vrhovec I
    Menstrual cycle and timing of breast surgery in premenopausal node-positive breast cancer: results of the International breast cancer study group (IBCSG) trial VI
    1997 ►
  33. Stanovnik M; Čufer T; Borštnar S; Pajk B
    Clinical study with interferon alpha-2A and cis-retinoic acid (CRA) in metastatic cancer of the kidney
    1998 ►
  34. Therasse P; Mauriac L; Welnicka M; Bruning P; Čufer T; Tomiak E; Curran D; Ramirez A; Koopmanschap M; Piccart M
    An EORTC-NCIC-SAKK neoadjuvant randomized phase III study comparing CEF (5FU, epirubicin, cyclophosphamide) vs dose intensified EC+G-CSF (filgrastim) in locally advanced breast cancer (LABC): updated results including quality of life
    1998 ►
  35. Pajk B; Čufer T; Zakotnik B; Borštnar S; Us-Krašovec M
    DNA ploidy as a predictive factor of tamoxifen treatment in elderly breast cancer patients stage I-III
    1998 ►
  36. Ocvirk J; Štabuc B; Čurin V; Žumec P
    Serum TNF-alpha and soluble TNF receptors p55 in melanoma patients
    1998 ►
  37. Raemaekers J; Burgers M; Henry-Amar M; Pinna A; Mandard A; Monfardini S; Hagenbeek A; Breed W; Carde P; Vovk M
    Patients with stage III/IV Hodgkin's disease in partial remission after MOPP/ABV chemotherapy have ecxellent prognosis after additional involved-field radiotherapy: interim results from the ongoing EORTC-LCG AND GPMC phase III trial
    1997 ►
  38. Goldhirsch A; Gelber RD; Castiglione M; O'Neill A; Thurlimann B; Rudenstam C-M; Lindtner J; Collins J; Forbes J; Crivellari D
    Menstrual cycle and timing of breast surgery in premenopausal node-positive breast cancer: results of the International breast cancer study group (IBCSG) trial VI
    1997 ►
  39. Noordijk EM; Carde P; Mandard AM; Mellink WAM; Monconduit M; Eghbali H; Tirelli U; Thomas J; Somers R; Vovk M
    Preliminary results of the EORTC-GPMC controlled clinical trial H7 in early-stage Hodgkin's disease
    1994 ►
  40. Ocvirk J; Štabuc B; Volk N
    Serum cathepsin D in melanoma patients with metastatic melanoma
    1996 ►
  41. Petrič-Grabnar G; Jančar J; Zidar A; Vovk M
    Anaplastic large cell lymphoma - Hodgkin's like (ALCL-HL): clinical evaluation of 19 patients treated as Hodgkin's disease from 1982 to 1990
    1996 ►
  42. Stucchi-Goldhirsch E; Forbes J; Price KN; Castiglione M; Gelber RD; Rudenstam C-M; Lindtner J; Collins J; Cavalli F; Cortes-Funes H
    Low-dose prednisone (p) in combination with adjuvant systemic therapy (AST) for operable breast cancer (BC) is associated with increased risk of second (non-breast) malignancies.
    1994 ►
  43. Marini G; Murray S; Goldhirsch A; Gelber RD; Castiglione-Gertsch M; Price KN; Tattersall MHN; Rudenstam C-M; Collins J; Lindtner J
    The effect of adjuvant prednisone combined with CMF on patterns of relapse and occurence of second malignancies in patients with breast cancer
    1996 ►
  44. Crivellari D; Price KN; Hagen M; Goldhirsch A; Gelber RD; Castiglione M; Coates AS; Rudenstam C-M; Collins J; Lindtner J
    Routine tests during follow-up of patients after primary treatment for operable breast cancer
    1995 ►
  45. Huerny C; Lindtner J; Novak J; Eržen D; Senčar M; Červek J; Cerar O; Štabuc B; Golouh R; Lamovec J; Jančar J; Šebek S
    Timing of baseline quality of life assessment in an international adjuvant breast cancer trial: its effect on patient self-estimation
    1994 ►
  46. Spataro V; Price K; Goldhirsch A; Cavalli F; Simoncini E; Castiglione M; Rudenstam CM; Collins J; Lindtner J; Gelber RD
    Sequential estrogen receptor determinations from primary breast cancer and at relapse: prognostic and therapeutic relevance
    1992 ►
  47. Goldhirsch A; Lindtner J; Novak J; Eržen D; Senčar M; Červek J; Cerar O; Štabuc B; Golouh R; Lamovec J; Jančar J; Šebek S
    The magnitude of endocrine effects of adjuvant chemotherapy for premenopausal breast cancer patients
    1990 ►
  48. Goldhirsch A; Lindtner J; Novak J; Naglas M; Červek J; Cerar O; Golouh R; Lamovec J; Jančar J; Šebek S
    Late effects of adjuvant oophorectomy and chemotherapy upon premenopausal breast cancer patients
    1990 ►

Nova poizvedba      Pripombe      Na vrh strani                        Inštitut za biostatistiko in medicinsko informatiko